Background/Aims: Prostate cancer (PCa) is one of the main cancers that damage males' health severely with high morbidity and mortality, but there is still no ideal molecular marker for the diagnosis and prognosis of prostate cancer. Methods: To determine whether the differentially expressed circRNAs in prostate cancer can serve as novel biomarkers for prostate cancer diagnosis, we screened differentially expressed circRNAs using SBC-ceRNA array in 4 pairs of prostate tumor and paracancerous tissues. A circRNA-miRNA-mRNA regulatory network for the differential circRNAs and their host genes was constructed by Cytoscape3.5.1 software. Quantitative real-time polymerase chain reaction analysis (qRT-PCR) was performed to confirm the microarray data. Results: We found 1021 differentially expressed circRNAs in PCa tumor using SBC-ceRNA array and confirmed the expression of circ_0057558, circ_0062019 and SLC19A1 in PCa cell lines and tumor tissues through qRT-PCR analysis. We demonstrated that combination of PSA level and two differentially expressed circRNAs showed significantly increased AUC, sensitivity and specificity (0.938, 84.5% and 90.9%, respectively) than PSA alone (AUC of serum PSA was 0.854). Moreover, circ_0057558 was correlated positively with total cholesterol. The functional network of circRNA-miRNA-mRNA analysis showed that circ_0057558 and circ_0034467 regulated miR-6884, and circ_0062019 and circ_0060325
Introduction
Prostate cancer (PCa) is one of the most common cancers in men worldwide, leading high mortality and morbidity, especially for elderly men. It is estimated that about 180, 890 men are diagnosed with prostate cancer in the United States in 2016, with approximately 26, 120 deaths caused by this cancer [1, 2] . Prostate cancer is a kind of heterogeneous disease which can present as either indolent or aggressive. Although most patients present with localized prostate cancer which is potentially curable by surgery or radiotherapy, up to 30% men will suffer relapse in 5-10 years, and rapid biochemical recurrence would result in prostate cancer-specific death in 10% of these patients [3] . The main therapy is prostatectomy for primary prostate cancer and androgen deprivation for metastatic disease, but for castrateresistant prostate cancer, treatment options are limited [4] . Thus, it is important to decide who needs treatments and who does not in order to avoid the unnecessary treatments that may result in severe complications and influence their quality of life without any survival benefits. At present, serum prostate-specific antigen (PSA) remains the standard biomarker for prostate cancer diagnosis and management. But the PSA test often lead to overdiagnosis and overtreatment due to its poor specificity [5] , there still is no consensus as to whether this screening test significantly reduces the rate of death from prostate cancer [6] . Moreover, the molecular mechanism of prostate cancer pathogenesis, invasion and metastasis remains largely unknown. It is important to identify the genetic drivers of prostate cancer in order to develop new biomarkers to stratify the risk and aggressiveness of prostate cancer at the time of screening.
Circular RNAs (circRNAs) as non-coding RNAs are endogenous single-stranded circular molecules formed by pre-mRNA back-splicing and characterized by abundant expression, high tissue specificity and stability [7, 8] . Scientists first discovered circRNAs in plantinfected viruses and Sendai virus in the 1970s and subsequently confirmed the extensive expression of circRNAs in fungal yeasts and animal cells [9] [10] [11] . Studies investigate that over 10% of expressed genes can produce circRNAs and the expression level of circRNAs is sometimes 10 times higher than that of their respective host genes [12] . circRNA has a closed ring structure with highly conservative sequence, therefore, it is not easy to be digested by RNase. Moreover, in saliva, blood and other body fluids, circRNAs can also be expressed stably [13, 14] . circRNAs play roles in the regulation of cell proliferation, apoptosis, angiogenesis and metastasis, suggesting that circular RNAs may involve in tumor formation [15, 16] and become novel biomarkers for the diagnosis and treatment of tumor [17] . circ_100290 could play a role of endogenous competitive RNA with the miR-29 family to regulate the expression of CDK6 in the development of oral cancer [18] . circ_0013958 played a role of miR-134 sponge and regulate the expression of cyclin D1 protein in the development of non-small cell lung cancer [19] . circ_100269 is down regulated in gastric cancer and inhibits the growth of gastric cancer cells by targeting miR-630 [20] . Lü investigated that the expression level of circ_103110, circ_104689 and circ_104821 were up-regulated in breast cancer tissues while those of circ_006054, circ_100219 and circ_406697 were down-regulated [21] . With the constant breakthrough and application of new technologies such as chip technology and second-generation sequencing, circular RNA has gradually become the focus of tumor genomics research [22] .
However, the differential expression of circRNAs in prostate cancer is rarely reported. Besides, the role of circRNAs in tumorigenesis and progression of prostate cancer remains largely unknown. In order to understand the molecular mechanism of circRNAs in prostate cancer, herein we investigated the differentially expressed profiles of circRNAs in prostate cancer using SBC Human competing endogenous RNAs (ceRNA) microarray and verified the RNA purification, SBC ceRNA Microarray, and Data analysis Total RNA was extracted and purified using Trizol reagent (Invitrogen) and RNeasy Mini Kit (Qiagen, USA) following the manufacturer's instructions. Total RNA was quantified by NanoDrop-2000 spectrophotometer (NanoDrop, USA), and assessed by Agilent Bioanalyzer 2100 (CA, US) to inspect RNA integration. SBC ceRNA microarray covers 88, 371 circRNAs, 68, 423 lncRNAs and 18, 853 mRNAs. Four pairs of prostate cancer and paracancerous tissues were used for microarray assay to investigate the differentially expressed circRNAs between cancer tissues and paracancerous tissues. Total RNA was amplified and labeled by Low Input Quick Amp WT Labeling Kit (Santa Clara, CA, US), Labeled cRNAs were purified by RNeasy mini kit. The microarray hybridization was performed following the manufacturer's standard protocols using Gene Expression Hybridization Kit (Santa Clara, CA, US) in Hybridization Oven (Santa Clara, CA, US). The hybridized slides were washed, fixed and finally scanned to images by Agilent Microarray Scanner (Santa Clara, CA, US). Data were extracted with Feature Extraction software 10.7 (CA, US), raw data were normalized by Quantile algorithm, limma packages in R. Significant differentially expressed circRNA between prostate cancer and paracancerous tissues were identified and retained by screening fold change > 2.0, p < 0.05.
Functional network analysis for the differential circRNAs and their host genes
To understand the role of differentially expressed circRNAs, Gene Ontology (GO) analysis and KEGG (Kyoto Encyclopedia of Genes and Genomes) were performed to construct meaningful annotation of genes as a whole network [23] . At the same time, we also constructed a circRNA-miRNA-mRNA network in transcripts. By analyzing the possible combination of circRNAs and miRNA, we predicted the target miRNAs of 100 circRNAs with the largest differences in ceRNA chip and draw a circRNA-miRNA regulatory network map. Then, we selected circRNAs that were verified to be differentially expressed in prostate cancer to further predict their target miRNAs and draw a circRNA-miRNA-mRNA regulatory network map by Cytoscape3.5.1 software. The miRNA binding sites of circRNAs were predicted by miRcode (http:// www.mircode.org/), while the potential miRNA response elements of mRNA were predicted by Targetscan (http://www.targetscan.org/). We performed qRT-PCR in a total reaction volume of 20 μl, including 10 μl of 2 x SYBR Green PCR buffer, 0.8 μl of Forward primer (10 μM), 0.8μl Reverse primer (10 μM), 0.4 μl of ROX reference Dye, 7 μl of ddH 2 O and 30 ng cDNA. The reaction was initiated at 95°C for 10min, then at 95°C (15s), 60°C (60s) for a total 40 cycles. 18S was used as an internal reference. Results were acquired from three independent wells. The relative expression level was calculated using 2 -ΔΔCt method. Student's t-tests were performed, and p < 0.05 was considered to be significant. The values were described as means ± SD.
Statistical analyses
We collected clinical data of the 173 prostate tissues and student's t-test was used to analyze the difference of circRNAs expression between prostate cancer group and BPH group. Pearson correlation analysis was used to investigate the relationship between differential circRNAs and clinical parameters. The results were regarded as statistically significant at p < 0.05. All graphs were built using GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). Statistical analysis was performed using the SPSS 20.0 (IBM-SPSS Inc., Chicago, IL, USA). Receiver operating characteristic (ROC) curves were applied to evaluate the clinical diagnostic value of differential circRNAs and the combination of PSA and circRNAs.
Results

Differential profiling of circRNAs and genes in prostate tumor
The probes of ceRNA microarray have been firstly used to detect a large number of transcripts in prostate cancer and corresponding paracancerous tissues. Scatter plots (Fig.  1A, B) and heatmap (Fig. 1C, D) of differential circRNAs and mRNAs in prostate tumor tissues and normal tissues were shown in Fig. 1 , The heatmap indicated that a total of 1021 circRNAs (Fig. 1C) and 250 mRNAs (Fig. 1D ) were differentially expressed with fold change > 2.0, p < 
0.05. Among them, 117 circRNAs and 66 mRNAs were upregulated, and 904 circRNAs and 184 mRNAs were dowregulated in four pairs of prostate cancer /adjacent tissues (Table 1) . Among the differential profiling of circRNAs, the most upregulated circRNA is circ_0057553 and the most downregulated circRNA is circ_0075541 which were produced by their host coding genes SLC39A10 and F13A1, respectively.
Functional pathway analysis of differential circRNAs, their host genes and regulatory networks
We predicted the functions of the differentially expressed circRNAs in prostate tumour through GO pathway enrichment analysis of their host genes and demonstrated that the host genes of these circRNAs are mainly involved in biological processes such as response to gonadotropin, trabecula morphogenesis, peptide cross-linking, regulation of blood coagulation and leukocyte cell-cell adhesion; the molecular functions of these host genes are mainly enriched in extracellular matrix (ECM) binding, ECM structural constituent, protease binding, growth factor binding and integrin binding; the cellular components of these host genes were involved in platelet alpha granule, ECM, external side of plasma membrane and adheren junction. The top 30 of GO analysis of these host genes of the 1021 differentially expressed circRNAs are shown in Fig. 2 . 
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Further, the target miRNAs of 100 circRNAs with the largest difference in ceRNA chip were predicted and five miRNAs with the most binding sites for each circRNAs were selected for subsequent analysis. The results showed that a total of 317 miRNAs were predicted from 100 differential circRNAs. On the other hand, circRNAs contain microRNA binding sites and act as miRNA sponges, thereby eliminating miRNAs' inhibitory effects on their target genes and increasing the target mRNA expression levels. Based on this endogenous competition mechanism, we first predicted the potential target miRNAs of circ_0057558, circ_0034467 (Table 2 ). Further, the target genes of these miRNAs were also predicted by IPA. Combining with the mRNA data of our prostate cancer profiling, we identified that 76 mRNAs including 17 upregulated and 59 down-regulated genes as targets of these miRNAs were differentially expressed in prostate tumor (Fig. 3) . To obtain insights into reciprocal circRNAs and mRNA regulation, a regulatory network of circRNAs-miRNAmRNA is constructed using the cytoscape software ( Fig. S1A -for all supplemental material see www.karger.com/10.1159/000494870/), which includes 4 circRNAs (circ_0057558, circ_0034467 circ_0062019, and circ_0060325), 12 related miRNAs (miR-15b-5p, miR-424-5p, miR-486-3p, miR-1273h-3p, miR-3678-3p, miR-4763-5p, miR-5008-5p, miR-6499-3p, miR-6721-5p, miR-6838-5p, miR-6884-3p, and miR-7843-5p,) and 76 target genes. We found that circ_0057558 and circ_0034467 can act together on miR-6884-3p to regulate 8 target genes; circ_0062019 and circ_0060325 work together on miR-5008-5p to regulate 21 target genes. It is noteworthy that the host gene SLC19A1 of circ_0062019 is also involved in this regulatory network. Thus, the specific regulatory patterns of circ_0062019 -miR-5008-5p -SLC19A1, circ_0060325 -miR-5008-5p -SLC19A1 and circ_0034467 -miR-6721-5p -SLC19A1 may be key regulators in prostate cancer (Fig. S1B) .
Validation of key differentially expressed circRNAs (circ_0075538, circ_0057558, and circ_0062019) and the host gene SLC19A1
We further verified the related differential circRNAs such as circ_0057558, circ_0062019, circ_0075538, and the host gene SLC19A1 in prostate cancer cells (PCa 22RV1, DU145, Lncap and PC3 cells), normal prostate cell HPEpiC and 173 prostate tissues (95 prostate cancer tissues and 78 BPH tissues) by qRT-PCR. The results revealed that circ_0057558 (Fig.  4A) and circ_0062019 (Fig. 4B) were up-regulated in four prostate cancer cells, which was consistent with the results of microarray. In addition, circ_0075538 is down-regulated in PC3 and 22RV1 cells (Fig. 4C) . At the same time, we found that SLC19A1 which is the host gene of circ_0062019 was also up-regulated in prostate cancer cells (Fig. 4D) . We further validated these circRNAs and SLC19A1 in 95 prostate cancer tissues and 78 BPH tissues. The results showed that circ_0057558 (Fig. 4E) and circ_0062019 (Fig. 4F) were up-regulated in prostate cancer tissues (p < 0.01). We also found that the host gene SLC19A1 was also up-regulated in PCa tissues (p < 0.01) (Fig. 4H) , which further confirmed the results of our ceRNA microarray although circ_0075538 was down-regulated in prostate cancer (p = 0.296) (Fig. 4G) .
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Differentially expressed circRNAs as novel biomarkers of prostate cancer associated with lipid metabolism, serum PSA levels and the progression of PCa
We assessed the diagnostic effectiveness of differential circRNAs to differentiate between prostate cancer and BPH tissues by ROC curve (Fig. 5) . The area under the curve (AUC) of circ_0062019, circ_0057558 and SLC19A1 were 0.828, 0.729 and 0.891, respectively (Fig.  5A -C, and Table 3 ). When two differential circRNAs were combined, the AUC is much better (0.861, Fig. 5D ) than PSA alone (which AUC of serum PSA was 0.854) although PSA is the main clinical indicator for early screening and diagnosis of prostate cancer, which demonstrated that different levels of these two circRNAs could help distinguish PCa patients from non-PCa patients and combing them could improve the diagnostic efficiency. We further analyzed the PSA level with the results of the 2 differential circRNAs. The results showed that the area of AUC was 0.938, the sensitivity was 84.5% and the specificity was 90.9% (Fig. 5E ). When we combined the circRNAs, PSA and SLC19A1, the AUC was up to 0.952 (Fig. 5F ). To clarify the characteristics these two differential circRNAs in prostate cancer, a Pearson correlation analysis was applied to analyze the correlation between these circRNAs and the corresponding clinical parameters. As shown in Table 4 , circ_0062019 is positively correlated with the age of the patients. circ_0062019 was also positively correlated with the patient's PSA level and Gleason score (p < 0.05). A combined Gleason score of 6 or 7 indicates PCa is likely to grow but may not spread quickly. A score of 8-10 means aggressive cancer which is the potentially lethal form of prostate cancer [24] . In this study, we investigated that the associate between the expression of circ_0062019, circ_0075538 and aggressive cancer (Gleason score 8-10, p < 0.05) (Table 5) , which indicates that the two circRNAs may be related to the progression of prostate cancer. We also found that circ_0057558 was positively correlated with total cholesterol (p = 0.04) ( Table 4 ), suggesting that circ_0057558 may be associated with lipid metabolism in prostate cancer patients. 
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Discussion
Prostate cancer is one of the most common cancers in developed countries such as Europe and the United States, and its mortality rate ranks the second in male malignancy [25] . The biological characteristics of PCa are complex and its early clinical symptoms are not severe enough to be noticed. At present, clinicians have limited indicators for the screening of prostate cancer among which the most commonly used one is PSA. However, the specificity of PSA is relatively low since it is also elevated in many benign prostate diseases. In addition, PSA is susceptible to many factors and lacks stability [13, 26] . Therefore, there is an urgent need to find new prostate cancer diagnostic markers for early screening of prostate cancer. In this study, four pairs of PCa and their corresponding paracancerous tissues were analyzed using ceRNA microarrays. A total of 1021 differential circRNAs including 117 up-regulated circRNAs and 904 down-regulated circRNAs were found in PCa tumor tissue. Next, we predicted the function of circRNAs by GO analysis for the host genes of the differential circRNAs in the chip. We found that the enrichment factor of gonadotropic response is the highest, involving genes such as NOTCH1, ICAM1, ITGA3 and TOX2 and related circRNAs such as circ_0089549, circ_0049237, circ_0044457, and circ_0008117. To further understand the role of differentially expressed circRNAs in PCa, we used circRNAs-miRNAmRNA network maps to predict the regulatory networks of circRNAs. We demonstrated that circ_0057558 and circ_0034467 work together on miR-6884-3p to regulate target genes such as AQP1, TUBA1A, LPAR1, EMP1, DHTK1, GINS2, DI03 and ITK; circ_0062019 and circ_0060325 act together on miR-5008-5p to regulate target genes such as CSF1, RAB3IL1, TGM2, GPR68, BIBD11, SIPR4, TGFB1I1, NUDT8, GPT2, while NPTX2. AQP1, LPAR1, TGFB1I1, CSF1 and NPTX2 have been reported in prostate cancer [7, 27] . It is of note that the target miRNA of circ_0057558 is miR-6884-3p. Although miR-6884-3p has not yet been reported, we analyzed the signal pathway database Reactome (http://www.reactome.org) and found that miR-6884-3p is involved in the metabolism of fatty acids, glycerol and ketone bodies and in triacylglycerols synthesis. We also found that circ_0057558 was significantly positively correlated with triglyceride levels, which suggested that circ_0057558 may regulate lipid metabolism in PCa by regulating miR-6884-3p.
qRT-PCR showed that circ_0062019 and circ_0057558 were up-regulated in four PCa cells, which were in full agreement with the results of the chip, suggesting that these circRNAs are highly expressed in the PCa. circ_0075538 was down-regulated only in PC3 and 22RV1 cells, which did not fully represent their expression level in prostate cells in vitro and needs further verification. In addition, we found that the host gene SLC19A1 of circ_0062019 was up-regulated in our ceRNA chip and also verified the gene in all the four prostate cells. The membrane protein encoded by SLC19A1 is a folate transporter which regulates the [28] [29] [30] . Tomaszewski collected serum folic acid levels in patients with PCa and analyzed the relationship between Ki67 and the level of serum folate and found that the proportion of Ki67 positive cells increased significantly in patients with high folate level, indicating that the level of folate in patients was related to the proliferation of PCa cells [31] . Therefore, SLC19A1 and its related circ_0062019 probably affect the progression of PCa by regulating the level of folate in vivo. We also validated that the expression of circ_0057558 and circ_0062019 and its host gene SLC19A1 were significantly up-regulated in PCa tissues (p < 0.01), which was in agreement with the cell verification results, indicating that the two circRNAs are likely to play an important role in the pathogenesis of PCa. Changes in lipid composition can influence membrane fluidity, cell growth and resistance to chemotherapeutic agents [32, 33] . PCa is a hormone-dependent cancer and the growth of cancer cells rely mainly on lipid oxidation [34] . It has been reported that there are lipid metabolism abnormalities in PCa patients and the lipid metabolism process is one of the major targets of PCa cell androgens since it is closely related to the growth, survival and drug resistance of PCa cells [35, 36] . Circ_0057558 was verified to be up-regulated in PCa and positively correlated with total cholesterol, which suggesting that circ_0057558 may promote the growth of PCa through the regulation of lipid metabolism in PCa patients. ROC curves were used to further evaluate the clinical diagnostic value of the two differential circRNAs. The results showed that the AUC of circ_0057558 and circ_0062019 was 0.729 and 0.828, respectively, Combined detection of circ_0057558 and circ_0062019 significantly improved the diagnostic specificity, sensitivity and AUC (0.824, 0.746 and 0.861, respectively) which were superior to those of PSA, through which we can better discriminate PCa from BPH.
Conclusion
In this study, we have screened two PCa related circRNAs-circ_0057558 and circ_0062019 in PCa. We found that when combining these two circRNAs with PSA, we can effectively distinguish between PCa and BPH patients. Therefore, these two differential circRNAs are expected to become potential biomarkers for PCa screening and diagnosis. Of note, the relationship between the differences in circRNAs and lipid metabolism need further investigation and verification with larger sample size to decide whether they can be applied in clinical practice for PCa.
